Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis

Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial)

“…As previously reported [ 12 , 13 , 14 , 15 , 16 , 17 , 20 ], our study also confirmed that TRG, HGP and pathological scores are important prognostic factors. TRG is the most widely used method to standardize pathological response evaluation [ 29 ] and is strongly associated with survival.…”

“…The BEV-ONCO trial was the first randomized study to compare preoperative administration of bevacizumab with either mFOLFOX6 or FOLFIRI in patients with resectable CRLM and evaluate pathological response as primary endpoint. Some retrospective studies already evaluated pathological response to assess the efficacy of the treatment in order to compare patients treated with chemotherapy alone (FOLFOX or FOLFIRI) and chemotherapy with anti-angiogenic treatment [ 14 , 15 , 16 ]. In particular, we previously reported that the percentage of MPRR (TRG < 3) was higher in patients who received bevacizumab with an oxaliplatin-based treatment (60% vs. 17% for irinotecan-based treatment) [ 16 ].…”

“…Several studies reported the prognostic survival relevance of some clinico-pathological parameters after CRLM surgery, such as size and the number of lesions [ 10 ], status of the surgical margin [ 11 ], pathological response (PR) assessed by tumor regression grading (TRG) [ 12 , 13 , 14 , 15 ], histopathological growth pattern (HGP) of liver metastases [ 16 , 17 ], molecular status assessed by the presence of RAS and BRAF mutations [ 3 , 18 ], chemotherapy-associated liver injury (CALI) [ 19 , 20 ] and Immunoscore [ 20 , 21 , 22 ]. We reported recently that a complete pathological evaluation of metastasis and surrounding liver parenchyma permitted the adequate stratification of resected mCRC patient prognosis [ 20 ].…”

“…Patients presenting a major pathological response rate (MPRR) (TRG < 3) had an improved 3-year DFS and 5-year OS compared with patients with no PR (TRG 4–5). Other retrospective studies [ 13 , 14 ] or meta-analysis [ 15 ] reported that patients treated with preoperative FOLFOX-Bevacizumab had a higher rate of MPRR compared to those with preoperative FOLFIRI-Bevacizumab treatment or chemotherapy alone.…”

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

“…We selected these two models because the liver is one of the dominant metastatic sites for colorectal cancer cells. 53,54 Measles, mumps, and rubella have been shown to not productively replicate in mouse cancer cells. [55][56][57][58] And OVs promote antitumor immunity against infected and uninfected cancer cells.…”